Stay updated on Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial
Sign up to get notified when there's something new on the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page.

Latest updates to the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page
- CheckyesterdayChange DetectedNew revision entry v3.6.5 appears in the study's history, replacing the prior v3.6.4 entry. This update affects the record's version history rather than the study data or trial details.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedRecord History now includes a new revision entry updating the version from v3.6.3 to v3.6.4. This reflects a maintenance release noted in the study's version history.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedA new page revision entry (v3.6.3) was added and the previous revision (v3.6.2) removed, updating the study record's revision history. This reflects an administrative update to the page's metadata rather than changes to the study data or visible content.SummaryDifference0.1%

- Check44 days agoChange DetectedA new version entry labeled Revision: v3.6.2 was added to the study's version history, and the previous entry Revision: v3.6.0 was removed.SummaryDifference0.1%

- Check59 days agoChange DetectedRecruitment status was updated to No longer looking for participants, indicating the study is not actively enrolling. The history shows a new revision (v3.6.0) and the previous revision (v3.5.5) has been removed to reflect the latest version of the record.SummaryDifference0.4%

- Check66 days agoChange DetectedA new revision entry (v3.5.5) was added to the study record history, updating the version history to reflect the latest revision. This change updates the historical log rather than the actual study data or visible content.SummaryDifference0.1%

Stay in the know with updates to Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Crizotinib in ALK, MET, ROS1 Alterations Clinical Trial page.